Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bioadaptives (BDPT) Accounts Payables (2016 - 2025)

Bioadaptives' Accounts Payables history spans 8 years, with the latest figure at $232725.0 for Q4 2025.

  • On a quarterly basis, Accounts Payables rose 29.68% to $232725.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $232725.0, a 29.68% increase, with the full-year FY2025 number at $232725.0, up 29.68% from a year prior.
  • Accounts Payables hit $232725.0 in Q4 2025 for Bioadaptives, up from $230768.0 in the prior quarter.
  • Over the last five years, Accounts Payables for BDPT hit a ceiling of $473501.0 in Q3 2024 and a floor of $57258.0 in Q1 2021.
  • Historically, Accounts Payables has averaged $312007.2 across 5 years, with a median of $358160.0 in 2022.
  • Biggest five-year swings in Accounts Payables: surged 467.47% in 2022 and later crashed 59.54% in 2024.
  • Tracing BDPT's Accounts Payables over 5 years: stood at $247750.0 in 2021, then soared by 65.46% to $409920.0 in 2022, then grew by 8.21% to $443579.0 in 2023, then crashed by 59.54% to $179458.0 in 2024, then rose by 29.68% to $232725.0 in 2025.
  • Business Quant data shows Accounts Payables for BDPT at $232725.0 in Q4 2025, $230768.0 in Q3 2025, and $204081.0 in Q2 2025.